UNCY
Unicycive Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.80
+0.63%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-39.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 28, 2026 | Kenkare-Mitra Sara · director | A-Award | 47,941 | $0.00 |
| Jul 28, 2026 | Laumas Sandeep · director | A-Award | 47,941 | $0.00 |
| May 21, 2026 | Gupta Shalabh K. · director, officer: CEO | A-Award | 762,200 | $0.00 |
| May 21, 2026 | Kenkare-Mitra Sara · director | A-Award | 84,200 | $0.00 |
| May 21, 2026 | Kenkare-Mitra Sara · director | A-Award | 42,100 | $0.00 |
| May 20, 2026 | Gupta Pramod · officer: EVP, Pharmaceuticals and BD | A-Award | 169,500 | $0.00 |
| May 20, 2026 | Jermasek Douglas · officer: EVP, Corporate Strategy | A-Award | 169,500 | $0.00 |
| May 20, 2026 | Townsend John · officer: CFO | A-Award | 169,500 | $0.00 |
| May 18, 2026 | Laumas Sandeep · director | A-Award | 42,100 | $0.00 |
| May 18, 2026 | Laumas Sandeep · director | A-Award | 84,200 | $0.00 |
| Jul 30, 2025 | Gupta Shalabh K. · director, officer: CEO | A-Award | 325,000 | $4.71 |
| Jul 30, 2025 | Jermasek Douglas · officer: EVP of Corporate Strategy | A-Award | 10,000 | $4.71 |
| Jul 30, 2025 | Gupta Pramod · officer: EVP, Pharmaceuticals and BD | A-Award | 90,000 | $4.71 |
| Jul 30, 2025 | Townsend John · officer: Chief Financial Officer | A-Award | 10,000 | $4.71 |
| Jul 30, 2025 | Laumas Sandeep · director | A-Award | 21,200 | $4.71 |
| Jul 30, 2025 | Aggarwal Gaurav · director | A-Award | 21,200 | $4.71 |
| Jul 30, 2025 | Kenkare-Mitra Sara · director | A-Award | 21,200 | $4.71 |
| Aug 14, 2024 | Townsend John · officer: Chief Financial Officer | A-Award | 40,256 | $0.34 |
| Aug 14, 2024 | Gupta Pramod · officer: EVP, Pharmaceuticals and BD | A-Award | 81,750 | $0.34 |
| Aug 14, 2024 | Jermasek Douglas · officer: EVP of Corporate Strategy | A-Award | 81,750 | $0.34 |
| Aug 14, 2024 | Gupta Shalabh K. · director, officer: CEO | A-Award | 232,868 | $0.34 |
| Apr 17, 2024 | Gupta Pramod · officer: EVP, Pharmaceuticals and BD | A-Award | 463,250 | $1.14 |
| Apr 17, 2024 | Gupta Shalabh K. · director, 10 percent owner, officer: CEO | A-Award | 1,319,583 | $1.14 |
| Apr 17, 2024 | Townsend John · officer: Chief Financial Officer | A-Award | 228,119 | $1.14 |
| Apr 17, 2024 | Jermasek Douglas · officer: EVP of Corporate Strategy | A-Award | 463,250 | $1.14 |
| Sep 7, 2023 | Kenkare-Mitra Sara · director | A-Award | 180,000 | $0.76 |
| Sep 7, 2023 | Aggarwal Gaurav · director | A-Award | 180,000 | $0.76 |
| Sep 7, 2023 | Laumas Sandeep · director | A-Award | 189,236 | $0.76 |
| Sep 7, 2023 | Ryan John L · director | A-Award | 112,147 | $0.76 |
| Aug 30, 2023 | Townsend John · officer: Chief Financial Officer | A-Award | 570,329 | $0.75 |
Institutional positioning
13F filings over the trailing two quarters
New 55Increased 36Reduced 20Sold out 8
| Filer | Action | Shares | Filed |
|---|---|---|---|
| VIVO CAPITAL, LLC | Unchanged | 1,789,916 | May 20, 2026 |
| BlackRock, Inc. | Increased | 1,413,381 | Aug 7, 2026 |
| Nantahala Capital Management, LLC | Increased | 1,401,447 | Aug 19, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 1,399,348 | May 15, 2026 |
| DIADEMA PARTNERS LP | Increased | 1,096,276 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 1,071,481 | Aug 13, 2026 |
| Octagon Capital Advisors LP | Unchanged | 1,000,000 | Aug 14, 2026 |
| OCTAGON CAPITAL ADVISORS LP | Unchanged | 1,000,000 | May 15, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Unchanged | 939,202 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 811,430 | May 15, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Increased | 809,639 | Aug 14, 2026 |
| GREAT POINT PARTNERS LLC | Unchanged | 796,558 | May 15, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Increased | 598,319 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 564,019 | Aug 12, 2026 |
| Vivo Capital, LLC | Reduced | 550,000 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 28, 2026